Which has preferable valuation & earnings, UPXI or IMRX?

Upexi has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Upexi $15.81M 3.70 -$13.68M -$0.62 N/A Immuneering N/A N/A -$56.03M -$1.17 N/A

Is UPXI or IMRX more profitable?

Immuneering has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Immuneering's return on equity of -31.93% beat Upexi's return on equity. Company Net Margins Return on Equity Return on Assets Upexi -874.00% -66.70% -19.56% Immuneering N/A -31.93% -29.92%

Does the media refer more to UPXI or IMRX?

In the previous week, Upexi had 1 more articles in the media than Immuneering. MarketBeat recorded 4 mentions for Upexi and 3 mentions for Immuneering. Immuneering's average media sentiment score of 1.59 beat Upexi's score of 0.94 indicating that Immuneering is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upexi 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immuneering 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings and valuation, SRZN or UPXI?

Upexi has higher revenue and earnings than Surrozen. Upexi is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Surrozen $3.48M 84.14 -$242.03M -$37.59 N/A Upexi $15.81M 3.70 -$13.68M -$0.62 N/A

Is SRZN or UPXI more profitable?

Upexi has a net margin of -874.00% compared to Surrozen's net margin of -4,810.50%. Upexi's return on equity of -66.70% beat Surrozen's return on equity. Company Net Margins Return on Equity Return on Assets Surrozen -4,810.50% -4,055.04% -154.08% Upexi -874.00% -66.70% -19.56%

Which has better earnings and valuation, UPXI or IVVD?

Upexi has higher earnings, but lower revenue than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Upexi $15.81M 3.70 -$13.68M -$0.62 N/A Invivyd $53.43M 4.91 -$52.49M -$0.31 N/A

Is UPXI or IVVD more profitable?

Invivyd has a net margin of -138.90% compared to Upexi's net margin of -874.00%. Invivyd's return on equity of -53.48% beat Upexi's return on equity. Company Net Margins Return on Equity Return on Assets Upexi -874.00% -66.70% -19.56% Invivyd -138.90% -53.48% -41.56%

Does the media favor UPXI or IVVD?

In the previous week, Upexi had 2 more articles in the media than Invivyd. MarketBeat recorded 4 mentions for Upexi and 2 mentions for Invivyd. Upexi's average media sentiment score of 0.94 beat Invivyd's score of 0.72 indicating that Upexi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upexi 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Upexi (UPXI) Competitors

$0.83 +0.07 (+9.64%)

Closing price 04:00 PM Eastern

Extended Trading

$0.82 -0.02 (-2.20%)

As of 04:53 PM Eastern

Compare

UPXI vs. RNAC, IMRX, SRZN, AKBA, and IVVD

Should you buy Upexi stock or one of its competitors? MarketBeat compares Upexi with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Upexi include Cartesian Therapeutics (RNAC), Immuneering (IMRX), Surrozen (SRZN), Akebia Therapeutics (AKBA), and Invivyd (IVVD). These companies are all part of the "pharmaceutical products" industry.

How does Upexi compare to Cartesian Therapeutics?

Cartesian Therapeutics (NASDAQ:RNAC) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Cartesian Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Upexi has a beta of -0.35, meaning that its stock price is 135% less volatile than the broader market.

Upexi has higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$1.78M	155.93	-$130.30M	-$5.90	N/A
Upexi	$15.81M	3.70	-$13.68M	-$0.62	N/A

In the previous week, Upexi had 3 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 4 mentions for Upexi and 1 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 1.87 beat Upexi's score of 0.94 indicating that Cartesian Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cartesian Therapeutics	Very Positive
Upexi	Positive

Cartesian Therapeutics currently has a consensus target price of $32.60, suggesting a potential upside of 246.07%. Upexi has a consensus target price of $8.33, suggesting a potential upside of 900.04%. Given Upexi's higher probable upside, analysts plainly believe Upexi is more favorable than Cartesian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

86.9% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of Upexi shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by company insiders. Comparatively, 9.0% of Upexi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Upexi has a net margin of -874.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Upexi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%
Upexi	-874.00%	-66.70%	-19.56%

Summary

Upexi beats Cartesian Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Upexi compare to Immuneering?

Upexi (NASDAQ:UPXI) and Immuneering (NASDAQ:IMRX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

5.7% of Upexi shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 9.0% of Upexi shares are owned by company insiders. Comparatively, 22.9% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Upexi has a beta of -0.35, meaning that its share price is 135% less volatile than the broader market. Comparatively, Immuneering has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Upexi currently has a consensus price target of $8.33, suggesting a potential upside of 900.04%. Immuneering has a consensus price target of $16.50, suggesting a potential upside of 247.30%. Given Upexi's higher probable upside, equities research analysts plainly believe Upexi is more favorable than Immuneering.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Immuneering has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Immuneering's return on equity of -31.93% beat Upexi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upexi	-874.00%	-66.70%	-19.56%
Immuneering	N/A	-31.93%	-29.92%

Upexi has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upexi	$15.81M	3.70	-$13.68M	-$0.62	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

In the previous week, Upexi had 1 more articles in the media than Immuneering. MarketBeat recorded 4 mentions for Upexi and 3 mentions for Immuneering. Immuneering's average media sentiment score of 1.59 beat Upexi's score of 0.94 indicating that Immuneering is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upexi	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immuneering	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Immuneering beats Upexi on 8 of the 15 factors compared between the two stocks.

How does Upexi compare to Surrozen?

Surrozen (NASDAQ:SRZN) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

In the previous week, Upexi had 2 more articles in the media than Surrozen. MarketBeat recorded 4 mentions for Upexi and 2 mentions for Surrozen. Surrozen's average media sentiment score of 1.43 beat Upexi's score of 0.94 indicating that Surrozen is being referred to more favorably in the media.

Company	Overall Sentiment
Surrozen	Positive
Upexi	Positive

Surrozen presently has a consensus target price of $42.00, suggesting a potential upside of 66.53%. Upexi has a consensus target price of $8.33, suggesting a potential upside of 900.04%. Given Upexi's higher possible upside, analysts clearly believe Upexi is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

66.6% of Surrozen shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 31.7% of Surrozen shares are held by insiders. Comparatively, 9.0% of Upexi shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Upexi has higher revenue and earnings than Surrozen. Upexi is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	84.14	-$242.03M	-$37.59	N/A
Upexi	$15.81M	3.70	-$13.68M	-$0.62	N/A

Upexi has a net margin of -874.00% compared to Surrozen's net margin of -4,810.50%. Upexi's return on equity of -66.70% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	-4,055.04%	-154.08%
Upexi	-874.00%	-66.70%	-19.56%

Surrozen has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Upexi has a beta of -0.35, meaning that its stock price is 135% less volatile than the broader market.

Summary

Surrozen and Upexi tied by winning 8 of the 16 factors compared between the two stocks.

How does Upexi compare to Akebia Therapeutics?

Upexi (NASDAQ:UPXI) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

5.7% of Upexi shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 9.0% of Upexi shares are owned by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Akebia Therapeutics has higher revenue and earnings than Upexi. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upexi	$15.81M	3.70	-$13.68M	-$0.62	N/A
Akebia Therapeutics	$236.20M	1.29	-$5.34M	-$0.08	N/A

Upexi currently has a consensus target price of $8.33, suggesting a potential upside of 900.04%. Akebia Therapeutics has a consensus target price of $4.67, suggesting a potential upside of 309.36%. Given Upexi's stronger consensus rating and higher possible upside, equities research analysts clearly believe Upexi is more favorable than Akebia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Akebia Therapeutics has a net margin of -8.83% compared to Upexi's net margin of -874.00%. Akebia Therapeutics' return on equity of -62.72% beat Upexi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upexi	-874.00%	-66.70%	-19.56%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

In the previous week, Upexi had 3 more articles in the media than Akebia Therapeutics. MarketBeat recorded 4 mentions for Upexi and 1 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 1.89 beat Upexi's score of 0.94 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Upexi	Positive
Akebia Therapeutics	Very Positive

Upexi has a beta of -0.35, meaning that its stock price is 135% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

Summary

Akebia Therapeutics beats Upexi on 10 of the 17 factors compared between the two stocks.

How does Upexi compare to Invivyd?

Upexi (NASDAQ:UPXI) and Invivyd (NASDAQ:IVVD) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Upexi has a beta of -0.35, indicating that its share price is 135% less volatile than the broader market. Comparatively, Invivyd has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

Invivyd has a net margin of -138.90% compared to Upexi's net margin of -874.00%. Invivyd's return on equity of -53.48% beat Upexi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upexi	-874.00%	-66.70%	-19.56%
Invivyd	-138.90%	-53.48%	-41.56%

In the previous week, Upexi had 2 more articles in the media than Invivyd. MarketBeat recorded 4 mentions for Upexi and 2 mentions for Invivyd. Upexi's average media sentiment score of 0.94 beat Invivyd's score of 0.72 indicating that Upexi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upexi	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Invivyd	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Upexi has higher earnings, but lower revenue than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upexi	$15.81M	3.70	-$13.68M	-$0.62	N/A
Invivyd	$53.43M	4.91	-$52.49M	-$0.31	N/A

Upexi currently has a consensus price target of $8.33, indicating a potential upside of 900.04%. Invivyd has a consensus price target of $8.00, indicating a potential upside of 797.87%. Given Upexi's stronger consensus rating and higher probable upside, analysts plainly believe Upexi is more favorable than Invivyd.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

5.7% of Upexi shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 9.0% of Upexi shares are held by insiders. Comparatively, 12.3% of Invivyd shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Invivyd beats Upexi on 9 of the 17 factors compared between the two stocks.

Get Upexi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UPXI vs. The Competition

Export

Metric	Upexi	Technology Services Industry	Business Sector	NASDAQ Exchange
Market Cap	$58.55M	$4.28B	$6.77B	$12.20B
Dividend Yield	N/A	2.06%	3.18%	5.90%
P/E Ratio	-1.34	40.44	28.41	24.19
Price / Sales	3.70	45.03	378.98	100.04
Price / Cash	N/A	35.92	22.49	53.91
Price / Book	0.83	4.60	5.78	6.36
Net Income	-$13.68M	$31.97M	$205.77M	$337.69M
7 Day Performance	-8.19%	-3.47%	-0.71%	-0.32%
1 Month Performance	-35.90%	-5.20%	-0.84%	0.33%
1 Year Performance	-73.63%	17.30%	25.53%	26.88%

Upexi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPXI Upexi	2.5467 of 5 stars	$0.83 +9.6%	$8.33 +900.0%	-77.2%	$58.55M	$15.81M	N/A	130	News Coverage
RNAC Cartesian Therapeutics	4.2368 of 5 stars	$9.05 +5.2%	$32.60 +260.2%	-17.0%	$265.89M	$2.80M	N/A	64	Positive News
IMRX Immuneering	3.5915 of 5 stars	$4.10 -2.1%	$16.50 +302.4%	+50.0%	$265.27M	N/A	N/A	60	Positive News Analyst Forecast
SRZN Surrozen	4.2019 of 5 stars	$22.75 -1.7%	$42.00 +84.6%	+181.8%	$264.13M	$3.48M	N/A	80	Positive News Short Interest Decrease
AKBA Akebia Therapeutics	2.1952 of 5 stars	$0.98 +4.8%	$4.67 +374.3%	-71.7%	$263.97M	$232.40M	N/A	430	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UPXI) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Upexi (UPXI) Competitors

UPXI vs. RNAC, IMRX, SRZN, AKBA, and IVVD

How does Upexi compare to Cartesian Therapeutics?

Summary

How does Upexi compare to Immuneering?

Summary

How does Upexi compare to Surrozen?

Summary

How does Upexi compare to Akebia Therapeutics?

Summary

How does Upexi compare to Invivyd?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPXI vs. The Competition

Upexi Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Upexi (UPXI) Competitors

UPXI vs. RNAC, IMRX, SRZN, AKBA, and IVVD

How does Upexi compare to Cartesian Therapeutics?

Which has more risk and volatility, RNAC or UPXI?

Which has preferable valuation & earnings, RNAC or UPXI?

Does the media prefer RNAC or UPXI?

Do analysts rate RNAC or UPXI?

Do insiders and institutionals hold more shares of RNAC or UPXI?

Is RNAC or UPXI more profitable?

Summary

How does Upexi compare to Immuneering?

Do insiders & institutionals have more ownership in UPXI or IMRX?

Which has more risk & volatility, UPXI or IMRX?

Do analysts prefer UPXI or IMRX?

Is UPXI or IMRX more profitable?

Which has preferable valuation & earnings, UPXI or IMRX?

Does the media refer more to UPXI or IMRX?

Summary

How does Upexi compare to Surrozen?

Does the media refer more to SRZN or UPXI?

Do analysts prefer SRZN or UPXI?

Do institutionals and insiders have more ownership in SRZN or UPXI?

Which has stronger earnings and valuation, SRZN or UPXI?

Is SRZN or UPXI more profitable?

Which has more risk and volatility, SRZN or UPXI?

Summary

How does Upexi compare to Akebia Therapeutics?

Do institutionals & insiders hold more shares of UPXI or AKBA?

Which has higher valuation & earnings, UPXI or AKBA?

Do analysts prefer UPXI or AKBA?

Is UPXI or AKBA more profitable?

Does the media favor UPXI or AKBA?

Which has more volatility & risk, UPXI or AKBA?

Summary

How does Upexi compare to Invivyd?

Which has more volatility & risk, UPXI or IVVD?

Is UPXI or IVVD more profitable?

Does the media favor UPXI or IVVD?

Which has better earnings and valuation, UPXI or IVVD?

Do analysts prefer UPXI or IVVD?

Do institutionals & insiders believe in UPXI or IVVD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPXI vs. The Competition

Upexi Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools